Archive for 2001

Merck Confirms Favorable Cardiovascular Safety Profile of Vioxx

May 22nd, 2001. In response to news and analyst reports of data the Company first released a year ago, Merck & Co., Inc. today reconfirmed the favorable cardiovascular safety profile of Vioxx(R) (rofecoxib), its medicine that selectively inhibits COX-2. Vioxx was approved by the Food and Drug Administration in May 1999 for the ... [More >>]

[ Goldberg, Persky & White, P.C. | 1030 Fifth Ave | Pittsburgh, PA 15219 | 800-471-3980 | Fax: 412-471-8308 | Email | Additional Offices ]

[ mesothelioma | nursing home abuse ]

Last Updated: February 05, 2008. 10:53:35 am

Pair